This activity is supported by an educational grant from Celgene and Merrimack Pharmaceuticals, Inc.
What Advanced Practitioners Need to Know About the Diagnosis and Treatment of Patients With Pancreatic Cancer
Joseph M. Herman, MD
University of Texas MD Anderson Cancer Center
Amy Hacker-Prietz, PA-C
Johns Hopkins University
Pancreatic cancer is known to carry a poor prognosis. Only 15%–20% of patients present with potentially resectable disease, and therefore accurate diagnosis and staging is essential. It is also important that providers are aware of emerging data and guidelines regarding second- and third-line treatment options. This educational activity will provide the advanced practitioner with important information regarding risk assessment, diagnostic workup, treatment considerations (including surgery, radiation, and chemotherapy), and supportive care.
These CE/CME/CEU accredited activities are jointly provided by